Results 151 to 160 of about 27,323 (260)

BLIMP‐1 and CD39 expression define human effector memory regulatory T cells in blood and recall responses to viruses

Immunology &Cell Biology, EarlyView.
This study found that BLIMP‐1 is highly expressed in activated effector/memory human regulatory T cells, especially CD39+ Tregs, where it is associated with increased IL‐10 production and a conserved phenotype across blood and lung tissues during immune responses such as SARS‐CoV‐2 infection.
Chansavath Phetsouphanh, Laura Cook, Katherine J. L. Jackson, Deirdre Cuff, Vera Klemm, Bikash Manandhar, Denise C. Hsu, Yin Xu, John J. Zaunders, Anthony D. Kelleher, Nabila Seddiki   +10 more
wiley   +1 more source

Recurrent cytokine release syndrome in patients receiving bispecific antibody therapy for multiple myeloma: a case series. [PDF]

Ann Hematol
Della Pepa R, Leone A, Grimaldi F, Avilia S, Memoli M, Rossini B, Liberatore C, Pane F.   +7 more
europepmc   +1 more source

A PD1‐CD137L Fusion Protein More Potently Enhances Anti‐Tumour Immune Responses Than Targeting PD‐L1 and CD137 Separately

Immunology, EarlyView.
A PD1‐CD137L fusion protein converts the immunoinhibitory PD‐L1 to an immunostimulatory signal and is more effective than targeting PD‐L1 and CD137 separately. ABSTRACT Tumour immune evasion frequently involves PD‐L1‐mediated inhibition of T cell activity, limiting the efficacy of PD1/PD‐L1 blockade, particularly in PD‐L1‐low or immunologically ‘cold ...
Runze Xia, Emily Pauline Nickles, Yu Mei, Thamizhanban Manoharan, Yi Tian Png, Beijia Liu, Rui Sun, Kang Yi Lee, Gloryn Chia, Chwee Ming Lim, Herbert Schwarz   +10 more
wiley   +1 more source

Case Report: Secondary neurolymphomatosis successfully treated with sequential Bruton's tyrosine kinase inhibitor and bispecific antibody therapy. [PDF]

Front Oncol
Oura M, Toho M, Ikeda D, Fukuda N, Torres AS, Fujii F, Sakuma H, Uehara A, Tabata R, Narita K, Takeuchi M, Matsue K.   +11 more
europepmc   +1 more source

Pathophysiology and emerging treatments for dermographic, cholinergic and cold urticaria

Journal of the European Academy of Dermatology and Venereology, EarlyView.
This review illustrates key proposed mast cell‐mediated activation pathways in dermographic, cholinergic and cold urticaria, highlighting IgE‐dependent and ‐independent mechanisms. These pathways are increasingly targeted by emerging drugs, aiming to interrupt mast cell activation and mediator release, offering more precise, mechanism‐based treatment ...
Mojca Bizjak‐Suran, Matjaž Fležar, Manuel Pedro Pereira   +2 more
wiley   +1 more source

Early mortality with bispecific antibody therapy in RRMM: an IMWG immunotherapy database real-world analysis. [PDF]

Blood Adv
Tan CR, Usmani S, Derkach A, de Meneze Silva Corraes A, Parrondo R, Ailawadhi S, Asoori S, Dave M, Popat R, Morjaria O, Hajek R, Mihalyova J, Htut M, Janakiram M, Visram A, Kastritis E, Dimopoulos MA, Martínez-López J, Nagarajan C, Bal S, Costa LJ, Einsele H, Steinbrunn T, Waldschmidt JM, Riedhammer C, Banerjee R, Chng WJ, Tso A, Lin Y, Martin T, Mian H.   +30 more
europepmc   +1 more source

Periodontitis and Rheumatoid Arthritis—Mechanistic Evidence

Journal of Periodontal Research, EarlyView.
Periodontitis and rheumatoid arthritis are linked via the two‐hit model whereby early periodontal inflammation can lead to autoantibody production capable of interacting with inflamed synovial tissues. Subsequent systemic inflammation can exacerbate the periodontal inflammatory response and bacterial dysbiosis leading to further autoantibody production
Mark Bartold, Chia Wei Cheah, Rathna Devi Vaithilingam   +2 more
wiley   +1 more source

IMM2510, a novel anti-PD-L1/VEGF bispecific antibody for cancer immunotherapy. [PDF]

Antib Ther
Chen D, Wu Z, Zhao X, Bhatt RS, Yang Y, Zhu W, Tang H, Wang K, Guo C, Liu D, Yang C, Guo H, Bai X, Zhang R, Li S, Tian W.   +15 more
europepmc   +1 more source

Beyond the chimeric antigen receptor T cells and bispecific antibody duopoly: ex vivo armed T cells for solid tumors. [PDF]

Front Immunol
Park JA, Cheung NV.
europepmc   +1 more source

The German ONKOPEDIA Guideline for Myelofibrosis in 2025—Recommendations of an MPN Expert Panel of the German Society for Hematology and Oncology (DGHO)

International Journal of Cancer, Volume 159, Issue 7, Page 1633-1641, 1 October 2026.
ABSTRACT The recently published ONKOPEDIA guideline on myelofibrosis, issued under the auspices of the German Society of Hematology and Oncology (DGHO), provides an updated, evidence‐based framework for the diagnosis and management of this rare, chronic myeloproliferative neoplasm.
Martin Griesshammer, Haifa Kathrin Al‐Ali, Gabriela M. Baerlocher, Konstanze Döhner, Steffen Koschmieder, Nicolaus Kröger, Petro E. Petrides, Dominik Wolf, Florian H. Heidel   +8 more
wiley   +1 more source